Carterra 23/09/25
LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Drug Discovery 2025, ELRIG – 04.07.2025
DDL 2025
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
HCMed

HCMed

On Drug Development & Delivery

HCmed Innovations is a CDMO specializing in inhalation drug delivery systems. Leveraging our proprietary vibrating mesh technology, we provide an integrated platform for the development of drug-device combination products, offering customized solutions for pharmaceutical partners.

Mesh Nebulizer Platforms

  • AdheResp®
    The first US FDA 510(k) cleared breath-actuated mesh nebulizer is equipped with built-in connectivity, and uniquely ready for large-scale manufacturing to support pharmaceutical partners in clinical trials—accelerating new drug development. Its characteristics enhance drug delivery efficiency and reduce fugitive aerosol emissions.
  • Pulmogine®
    A continuous-delivery vibrating mesh nebulizer that efficiently aerosolizes liquid medications. With its compact size and quiet operation, it offers a comfortable and user-friendly nebulization experience.

Flexible Customization Options

  • Level 1 Mesh
    We offer a wide selection of mesh membranes to optimize aerosol performance for your formulation needs.
  • Level 2 Firmware
    Our customizable firmware empowers you to tailor the functional features precisely to your requirements.
    Define the optimal triggering span for each breathing cycle, and include other features such as NFC-based activation and Bluetooth connectivity to provide to monitor adherence
  • Level 3 Hardware
    Our customizable hardware platform empowers the tailoring of the device’s aesthetic design, components, and usability from technical specifications in the board to precise usability requirements, delivering a truly personalized solution.

Through our tailored services, we optimize aerosol delivery across a broad range of therapeutic formulations—from small molecules to complex biologics. With the capability to nebulize a wide array of high-value therapeutic drugs, we conquer limitations for inhaled medications.

End-to-End Development for Combination Products

HCmed provides full-spectrum support from early-stage feasibility through clinical trials and commercial supply. Our integrated approach ensures alignment between drug formulation and device performance, allowing seamless transition across development phases. Whether optimizing aerosol characteristics or supporting regulatory submissions, we help partners de-risk development and shorten timelines for bringing combination products to market.

Your One-stop Partner

Combining technical expertise and flexible solutions, we help deliver high-performance inhalation systems tailored to each pharmaceutical partners’ needs—from small molecules to biologics. HCmed is your trusted partner in developing and commercializing inhaled combination products.

HCmed Website:https://www.hcmed-inno.com

YPSOMED website ad
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025